分子生物标志物是套细胞淋巴瘤结局的关键决定因素:FIL V-RBAC 试验结果
研究对FIL V-RBAC二期试验中140例老年套细胞淋巴瘤患者中的132例进行146基因深度测序,ATM突变最常见(55例,41.7%),TP53与KMT2D各31例(23.5%)。除TP53突变外,CDKN2A缺失、CD36突变及单打击ATM异常独立影响无进展生存,整合为四因素分子预后模型并内部验证。
要点
- 老年MCL中ATM突变率41.7%,TP53与KMT2D各23.5%,CDKN2A缺失22%。
- CDKN2A缺失、CD36突变、单打击ATM异常独立关联无进展生存。
- 无其他风险因素的单打击ATM异常患者获持久长期缓解,CD36突变者生存不良。
核心结论
- 除TP53突变外,CDKN2A缺失、CD36突变和单打击ATM异常是MCL独立的预后分子标志。
- 四因素分子预后模型可区分四个预后显著不同的患者亚组。
- 结果支持在MCL中开展分子分型并整合TP53以外标志物进行风险分层。
研究设计与样本
- FIL V-RBAC为二期试验,纳入140例老年MCL患者,132例有可用基因组DNA纳入分析。
- 采用靶向146个MCL相关基因的深度测序检测突变和拷贝数变异。
- 预后模型通过bootstrapping方法进行内部验证。
主要发现
- ATM突变55例(41.7%),TP53和KMT2D各31例(23.5%)。
- ATM缺失32例(24%),CDKN2A缺失29例(22%)。
- CDKN2A缺失、CD36突变和单打击ATM异常在校正Ki-67≥30%和母细胞样变异后独立关联无进展生存。
- 无其他风险因素的单打击ATM异常患者获得持久长期缓解,CD36突变与不良生存相关。
关键数值与推荐
- ATM突变频率41.7%(55/132)。
- TP53和KMT2D突变频率各23.5%(31/132)。
- ATM缺失频率24%(32/132),CDKN2A缺失频率22%(29/132)。
- 高危试验定义特征为Ki-67≥30%和母细胞样变异。
临床怎么用
- 对老年MCL患者可考虑进行包含ATM、TP53、KMT2D、CDKN2A和CD36的分子检测。
- 单打击ATM异常且无其他风险因素者可能适合期待或低强度策略。
- CD36突变提示不良生存,需更积极治疗或密切监测。
局限性
- 研究为二期试验的事后分析,样本量有限(132例)。
- 预后模型仅通过bootstrapping内部验证,缺乏外部验证。
- 结论基于老年MCL人群,外推至年轻患者需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study comprehensively dissects the molecular landscape of older patients with mantle cell lymphoma (MCL) enrolled in the phase 2 FIL V-RBAC trial of the Fondazione Italiana Linfomi (FIL). Of the 140 patients enrolled, 132 had available genomic DNA extracted from lymph node biopsies or bone marrow aspirates and were included in the analysis. A cancer personalized profiling by deep sequencing assay targeting 146 genes relevant to MCL pathogenesis was used to identify gene mutations and copy number variations. ATM was the most frequently mutated gene, detected in 55 patients (41.7%), followed by TP53 and KMT2D in 31 patients (23.5%). ATM deletion was observed in 32 patients (24%), whereas CDKN2A loss was observed in 29 (22%). Beyond TP53 mutations, 3 other molecular lesions, including CDKN2A loss, CD36 mutations, and single-hit ATM abnormalities (either mutation or deletion), were independently associated with progression-free survival after adjustment for high-risk trial-defining features, namely Ki-67 ≥30% and blastoid variant. Notably, patients harboring single-hit ATM alterations without any additional risk factors achieved durable long-term remission, whereas CD36 mutations were associated with adverse survival. Both findings represent previously unrecognized aberrations in this cohort that were independently and inversely associated with survival. The 4 variables were integrated into a 4-factor molecular prognostic model internally validated using a bootstrapping approach, which identified 4 distinct patient subgroups with significantly different outcomes. These findings support the importance of (1) molecular profiling in MCL, (2) risk-adapted trials such as FIL V-RBAC, and (3) the integration of other biological markers with TP53 mutations for a more precise risk assessment in MCL. This trial was registered at www.clinicaltrials.gov as NCT03567876.
引用
- Moia R, Almasri M, Carazzolo ME, et al. Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial. Blood Adv. 2026. PMID: 42498280. doi:10.1182/bloodadvances.2026020780
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。